Literature DB >> 26450002

Fibroblast Growth Factor-23 Fans the Flames of Heart and Kidney Failure.

Myles Wolf1, Rupal Mehta2.   

Abstract

Entities:  

Keywords:  cardiovascular disease; chronic kidney disease; fibroblast growth factor-23; heart failure

Mesh：

Substances：

Year:  2015        PMID： 26450002      PMCID： PMC5508572          DOI： 10.1016/j.jchf.2015.07.008

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN： 2213-1779            Impact factor:   12.035


× No keyword cloud information.
  14 in total

1.  FGF23 induces left ventricular hypertrophy.

Authors:  Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

Review 2.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

3.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Authors:  Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf
Journal:  JAMA       Date:  2011-06-15       Impact factor: 56.272

4.  Fibroblast growth factor-23 and cardiovascular events in CKD.

Authors:  Julia J Scialla; Huiliang Xie; Mahboob Rahman; Amanda Hyre Anderson; Tamara Isakova; Akinlolu Ojo; Xiaoming Zhang; Lisa Nessel; Takayuki Hamano; Juan E Grunwald; Dominic S Raj; Wei Yang; Jiang He; James P Lash; Alan S Go; John W Kusek; Harold Feldman; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2013-10-24       Impact factor: 10.121

5.  FGF23 is associated with disease severity and prognosis in chronic heart failure.

Authors:  Gerhard Poelzl; Christian Trenkler; Johannes Kliebhan; Philipp Wuertinger; Christoph Seger; Susanne Kaser; Gert Mayer; Markus Pirklbauer; Hanno Ulmer; Andrea Griesmacher
Journal:  Eur J Clin Invest       Date:  2014-11-03       Impact factor: 4.686

6.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

7.  Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23.

Authors:  Richard Marsell; Tijana Krajisnik; Hanna Göransson; Claes Ohlsson; Osten Ljunggren; Tobias E Larsson; Kenneth B Jonsson
Journal:  Nephrol Dial Transplant       Date:  2007-10-02       Impact factor: 5.992

8.  Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.

Authors:  Jacob A Udell; David A Morrow; Petr Jarolim; Sarah Sloan; Elaine B Hoffman; Thomas F O'Donnell; Amit N Vora; Torbjørn Omland; Scott D Solomon; Marc A Pfeffer; Eugene Braunwald; Marc S Sabatine
Journal:  J Am Coll Cardiol       Date:  2014-04-09       Impact factor: 24.094

9.  Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure.

Authors:  Peter Wohlfahrt; Vojtech Melenovsky; Martin Kotrc; Jan Benes; Antonin Jabor; Janka Franekova; Sophia Lemaire; Josef Kautzner; Petr Jarolim
Journal:  JACC Heart Fail       Date:  2015-10       Impact factor: 12.035

10.  Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community.

Authors:  Johan Ärnlöv; Axel C Carlsson; Johan Sundström; Erik Ingelsson; Anders Larsson; Lars Lind; Tobias E Larsson
Journal:  Kidney Int       Date:  2012-09-05       Impact factor: 10.612
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.